Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults (NCT01745380), a randomized phase 3 study. The primary outcome is Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic..

2. Clinical Question

The comparison is framed around a concrete procedural result: whether the dental procedure could be completed without an injection of rescue local anesthetic. This is distinct from measuring a continuous degree of pain relief or the duration of anesthesia. The registry summary describes the study purpose as comparing the efficacy of Kovacaine Mist and placebo for inducing pulpal anesthesia of the maxillary teeth in adults, while the posted primary outcome operationalizes success as procedure completion without rescue.

The registry record identifies a randomized, triple-masked, parallel-groups phase 3 trial. It does not describe which parties were masked, the exact details of the dental procedure, or additional participant characteristics. The primary outcome therefore answers the recorded procedural question for the enrolled study population; it should not be taken to establish results for patient groups, procedures, or circumstances that the registry record does not characterize.

3. Trial Design

The registry record describes a phase 3, multicenter, randomized, triple-masked, parallel-groups trial. Participants were assigned to Kovacaine Mist or placebo. The posted arm counts are 100 for Kovacaine Mist and 50 for placebo; the registry enrollment is 150. The record does not explain the allocation ratio or report the sequence-generation or concealment procedures, so those details cannot be assessed from the registry record.

The active intervention is listed as tetracaine HCl 3% and oxymetazoline HCl 0.05%. The arm description states that 2 sprays were administered at the start of the procedure, with a third spray if anesthesia was insufficient. The placebo arm is described with the same spray schedule. The registry record does not give further details about administration, treatment adherence, or how the decision that anesthesia was insufficient was made.

The primary outcome is the number of participants who completed the study dental procedure without rescue injection of local anesthetic. Its assessment timeframe is 15 minutes, with a +3 minute window. Participants needing rescue injection were classified as failures for this outcome. Secondary outcomes include additional measures of procedure completion by age group and measures concerning heart rate and blood pressure. The record lists 16 outcome measures, but only 14 secondary outcomes are identified as posted in the analyzed record.

The study status is completed. The start and primary-completion entries are 2013-02 and 2013-05. The registry record does not report the protocol’s original sample-size justification, the trial’s planned statistical analysis details, the identities of the parties included in triple masking, or the participant flow through screening and follow-up. Those absences limit assessment of design implementation beyond the elements explicitly recorded.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic., measured over at 15 minutes, +3 minute window.

The primary endpoint counts participants who completed the study dental procedure without needing rescue injection of local anesthetic. The registry specifies assessment at 15 minutes, with a +3 minute window. If anesthesia was insufficient to complete the procedure, rescue injection was given and the participant counted as a failure for this outcome. Thus the event being counted is successful procedure completion without rescue, rather than receipt of rescue treatment.

This endpoint is useful because it translates the study’s anesthesia question into a clear procedural outcome. A count of participants completing the procedure without rescue reflects whether the initial assigned approach was sufficient for the defined task, while the failure rule incorporates rescue injection directly into the outcome definition. It is therefore interpretable in terms of procedure completion, rather than requiring a reader to infer what a change in an anesthesia score might mean for the procedure.

The measure is binary at the participant level: each participant is counted as having completed the procedure without rescue or not having done so. It does not, by itself, describe the intensity or duration of anesthesia, the experience of participants who completed without rescue, or the reasons for needing rescue. The registry record does not report additional details about outcome adjudication or the specific procedure. Interpretation should therefore remain tied to the recorded endpoint and timeframe.

7. Results Posted in the Registry

• Kovacaine Mist: 88.0% (88/100) versus 28.0% (14/50) on control; risk difference 60.0 percentage points (95% CI 46.0 to 74.0), risk ratio 3.14 (2.00–4.93); unadjusted two-proportion z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Number of Participants With a Heart Rate Lower Than 50 Bpm

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Kovacaine Mist: 4.0% (4/100) versus 2.0% (1/50) on control; risk difference 2.0 percentage points (95% CI -3.5 to 7.5), risk ratio 2.00 (0.23–17.43); unadjusted two-proportion z-test p = 0.520.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Kovacaine Mist and the control. The interval gives the range of effects that remain compatible with the data.

Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and/or to a Value Higher Than 160 mm Hg

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Kovacaine Mist: 5.0% (5/100) versus 4.0% (2/50) on control; risk difference 1.0 percentage points (95% CI -5.9 to 7.9), risk ratio 1.25 (0.25–6.22); unadjusted two-proportion z-test p = 0.784.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Kovacaine Mist and the control. The interval gives the range of effects that remain compatible with the data.

Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and/or to a Value Lower Than 90 mm Hg

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Kovacaine Mist: 1.0% (1/100) versus 2.0% (1/50) on control; risk difference -1.0 percentage points (95% CI -5.3 to 3.3), risk ratio 0.50 (0.03–7.83); unadjusted two-proportion z-test p = 0.615.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Kovacaine Mist and the control. The interval gives the range of effects that remain compatible with the data.

The secondary outcomes extend the primary procedural question with a reported age-group analysis of completion without rescue and several heart-rate and blood-pressure measures. The posted event outcomes concern thresholds observed after administration, rather than the primary question of completing the dental procedure without rescue. They therefore address related aspects of the study but measure different things.

Across the posted cardiovascular event outcomes, the counts are small and the confidence intervals for the risk differences include zero. The point estimates do not form a consistent, precise pattern that would support a firm comparative conclusion. The registry record also lists a maximum-change heart-rate outcome, but no result for that outcome is included in the secondary results described in the record. The record identifies 14 secondary outcomes as posted and does not report analyses for them in a separate analysis listing.

The secondary results do not negate or independently confirm the primary result. The primary endpoint asks whether the procedure was completed without rescue; the secondary safety-related endpoints ask whether specified cardiovascular thresholds were recorded. Different outcome definitions can produce different patterns, and an absence of a clear difference in a sparse secondary measure is not evidence that the two arms are equivalent for that measure.

Unadjusted secondary results carry less weight because multiple outcomes create more opportunities for apparently notable findings, and the registry record does not report a multiplicity adjustment. It also does not report which secondary comparisons were prespecified, how missing secondary measurements were handled, or whether any subgroup analyses were planned. These limitations counsel against selecting an isolated secondary result as definitive. The secondary outcomes are best treated as descriptive context alongside the primary endpoint, with attention to their event counts, intervals, and unreported analysis details.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic by Age Group (≤50 and >50 Years)
• Number of Participants With a Heart Rate Higher Than 125 Bpm
• Number of Participants With a Heart Rate Lower Than 50 Bpm
• Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and/or to a Value Higher Than 160 mm Hg
• Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and/or to a Value Lower Than 90 mm Hg
• Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and/or to a Value Higher Than 105 mm Hg
• Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 10 mm Hg and/or to a Value Lower Than 50 mm Hg
• Maximum Change From Baseline in Heart Rate

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is binary: each participant either completed the procedure without rescue injection or did not. For binary outcomes, a risk is the proportion of participants in an arm with the event being counted. Here the event is completion without rescue, not need for rescue. Comparing the two arm-specific risks is a direct way to summarize how often that recorded outcome occurred in each group.

What does the risk difference express?

The posted risk difference is 0.6 for Kovacaine Mist relative to placebo. A risk difference subtracts the comparator-arm risk from the intervention-arm risk, so a positive value indicates that the event was more frequent in the intervention arm. In this trial, the event is successful completion without rescue. The risk difference is expressed on the probability scale and describes the size of the observed contrast in absolute terms. It does not adjust for other participant characteristics.

The risk difference is not the only possible summary. A risk ratio compares the two arm-specific risks by division, and an odds ratio compares their odds. Those measures answer related but not identical questions and can have different numerical magnitudes, especially when an outcome is common. The registry record posts a risk ratio of 3.143, with interval limits 2.003 and 4.931, and an odds ratio of 18.86, with interval limits 7.955 and 44.7. These relative measures complement rather than replace the absolute risk difference. The outcome definition must remain clear when interpreting any of them.

How should the confidence interval be understood?

A confidence interval describes statistical uncertainty around an estimate under the assumptions of the analysis. It is not a range that guarantees where the true effect lies, nor does it show the spread of individual participant outcomes. For the primary risk difference, the posted interval lies above zero. That is consistent with the direction of the observed group difference and indicates that the interval does not include no difference. The width of an interval also matters: a narrower interval generally indicates greater precision, while a wider one leaves more uncertainty about the effect’s magnitude.

What does the p-value contribute?

The primary unadjusted p-value is <0.001. In general, a p-value describes how incompatible the observed data are with a specified null model, assuming that model and the analysis assumptions hold. It is not the probability that the null hypothesis is true, and it does not measure the probability that the result is due to chance. Nor does a small p-value establish clinical importance. The effect estimate and its interval provide information about direction and magnitude that a p-value alone cannot provide.

“Unadjusted” means that the reported comparison is not described as controlling for other variables or for the set of multiple outcomes. It is a comparison of the posted group summaries. The registry record does not report a model for the primary outcome, covariate adjustment, or further details about its inferential procedure. These omissions mean that the posted comparison should not be read as evidence of a particular adjusted analysis.

Why do small counts affect interpretation?

Several secondary outcomes are rare in the posted data, with only a few participants recorded with an event in an arm. When counts are sparse, estimates can be imprecise and sensitive to small changes in the observed counts. A confidence interval may therefore span effects in more than one direction, even when the point estimate favors one arm. This is one reason not to treat the direction of a secondary point estimate as conclusive.

For outcomes measured as counts of participants with an event, the number affected and the number at risk should be considered together. A raw count alone does not account for the size of its arm. The posted comparisons express the outcome as a difference between arm risks, while the arm-level counts show the underlying event frequency. The registry record provides no additional model-based secondary analyses.

What is not established by the analysis?

Statistical significance and clinical importance are separate questions. The primary comparison has a small reported p-value and an interval above zero, but the registry record does not specify a threshold for a clinically meaningful risk difference. Nor does it report whether the analyses were prespecified in a protocol, what populations were included in each analysis, or whether any interim review was conducted. Such details are not reported in the registry record and should not be inferred from the posted summary statistics.

All statistical explanations in this discussion are general descriptions of how these measures are commonly interpreted. The record does not provide the complete analysis plan or enough detail to independently assess every modeling or data-handling choice. The trial’s observed counts remain the basis for the reported comparison; the methods discussion clarifies what those summaries mean without extending them to unreported analyses.

11. Confidence Intervals and Precision

The primary risk difference is 0.6, and its posted confidence interval lies entirely above zero. This supports the conclusion that the observed arm-level contrast is not close to no difference under the reported interval calculation. The interval nevertheless represents uncertainty about the size of the difference; it does not make the estimate exact. The primary arm counts are 88 of 100 participants and 14 of 50 participants, so the comparison is based on different arm sizes.

Precision should be judged from the interval, not from the p-value alone. A p-value addresses compatibility with a null model, while an interval communicates a range of estimates consistent with the data and the method. An interval that excludes zero can still allow a range of possible positive effects. The registry record does not report a clinical threshold that would distinguish a small but statistically detectable difference from a clinically important one.

The secondary estimates are less precise where event counts are small. Their confidence intervals include zero for the posted risk differences, leaving uncertainty about the direction and magnitude of those comparisons. This is not evidence that the arms are equivalent; the intervals do not establish equivalence, and the registry record does not report an equivalence or noninferiority design.

These intervals are based on the posted summary data and should be read as uncertainty summaries for the stated comparisons. They do not account for unreported sources of uncertainty such as missing outcome data, deviations from assigned treatment, or selection into the analysis population. The registry record does not give enough detail to determine how those issues were handled. Precision in the calculated contrast is therefore distinct from certainty about the broader clinical interpretation.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are illustrations based on the observed effect, not the trial’s original design calculation. The planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each planning scenario asks how many participants per arm would be needed to detect the stated fraction of the observed effect. The scenarios use 100% of the observed effect, 75% of the observed effect, and 50% of the observed effect.

The 80% power column gives the illustrative participants per arm for a design with an 80% probability of detecting the specified effect under the stated assumptions, if that effect were the true one and the assumptions held. The 90% power column gives the corresponding participants per arm for a design targeting a 90% probability. These are design-planning quantities, not a measure of the probability that the completed trial’s finding is correct.

For the primary outcome, the planning values are 10 participants per arm for 80% power and 12 for 90% power when planning for 100% of the observed effect. For 75% of the observed effect, the corresponding figures are 19 and 24 participants per arm. For 50% of the observed effect, they are 42 and 56 participants per arm. The pattern illustrates a general principle: smaller effects are harder to detect, so planning for a smaller effect requires more participants.

These planning numbers are not observed power. They do not show that the completed trial had a particular probability of producing a significant result after its observed data were collected. They also do not recover the study’s original design assumptions, which are not reported in the registry record. The illustration uses the observed primary effect as its starting point; results from other outcomes have their own planning values and may be especially sensitive to sparse event counts.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.280; treatment proportion p₁ = 0.880; average p̄ = 0.580.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.6980 = 1.3680.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.5543 = 0.4665.
4. n = (1.3680 + 0.4665)² / (0.6000)² = 9.3, rounded up to 10 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.28                          # control proportion
p1 <- 0.88                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(1745380)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 10 (80% power), 12 (90% power)
 75% of observed effect: n per arm = 19 (80% power), 24 (90% power)
 50% of observed effect: n per arm = 42 (80% power), 56 (90% power)
power.prop.test: 9.3 
Simulated power at n = 10 per arm: 0.814 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry record lists 16 outcome measures, with 14 secondary outcomes identified as posted. Considering several outcomes creates a multiplicity issue: even if no underlying differences exist for the outcomes being tested, repeated comparisons can make at least one apparently unusual result more likely. Statistical approaches can address this by adjusting inference or by defining a hierarchy of outcomes, but the registry record does not report a multiplicity procedure or a hierarchy for interpreting the secondary outcomes.

The primary result is distinct from the collection of secondary comparisons, but the record does not include a protocol or a statistical analysis plan that would establish which analyses were prespecified. It does not report interim analyses, data-monitoring rules, or stopping criteria. Those items are not reported in the registry record, so their absence from the public summary cannot be treated as proof that they were or were not used.

The record also does not state the analysis population for the primary or secondary outcomes. It does not describe whether participants were analyzed according to randomized assignment, whether there was a per-protocol or safety population, or how participants with incomplete outcome data were handled. A participant flow diagram, reasons for missing outcomes, and an account of exclusions are not reported in the registry record. The posted arm counts and event counts alone cannot resolve these questions.

These omissions matter because the meaning of an estimate depends on who was included and how missing observations were treated. If outcome availability differed between arms, or if analysis populations differed from the randomized groups, the observed comparison could have a different interpretation from a complete intention-to-treat analysis. No such difference is established by the registry record; the relevant methods are simply not reported there.

The record reports zero analyses in its analysis listing. That does not mean no statistical work was performed; it means that the registry record does not supply a separate reported analysis entry for review. The posted primary comparison remains interpretable as an unadjusted comparison of the reported summaries, but detailed multiplicity control, analysis populations, missing-data methods, and interim procedures cannot be evaluated from this record.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The posted serious adverse event figures are zero affected participants in the Kovacaine Mist arm among 100 at risk and zero in the placebo arm among 50 at risk. These counts mean that the registry record reports no participants with a serious adverse event in either arm for the listed safety results. They do not establish that serious events are impossible or that the treatments have identical safety profiles; zero observed events in a trial does not rule out events that were not observed.

The record lists other adverse events affecting 83 participants in the Kovacaine Mist arm and 15 participants in the placebo arm. These are separate from the serious adverse event figures and should not be combined with them as though they were the same category. The registry record does not provide the adverse-event terms, severity breakdown, relationship assessments, duration, or withdrawal consequences in the registry record recorded for this analysis.

Deaths are not reported in the registry record. That should not be read as a zero count. The safety summary is limited to the posted counts and does not provide enough detail to assess the nature or clinical significance of individual events.

16. What the Result Does, and Does Not, Mean

The primary result describes a difference in a specific outcome: completion of the study dental procedure without rescue injection of local anesthetic, measured at 15 minutes with a +3 minute window. In the posted data, that outcome occurred more often in the Kovacaine Mist arm than in the placebo arm. The estimated risk difference is 0.6, the confidence interval lies above zero, and the reported unadjusted p-value is <0.001. These statistics describe the comparison within the trial as recorded.

The result does not establish that every participant receiving Kovacaine Mist would complete every dental procedure without rescue, or that the same result would occur in populations and settings not described in the registry record. The record does not report enough detail about eligibility, participant characteristics, dental procedures, or clinical practice conditions to define the full reach of the finding. Nor does the endpoint measure every aspect of pain relief, comfort, duration, or anesthesia quality.

Statistical evidence of a difference is not the same as evidence that the size of the difference is clinically important. The registry record does not specify a minimum clinically important difference or a decision threshold. It also does not provide an adjusted analysis or a detailed account of missing data and analysis populations. Those limitations do not erase the posted result, but they constrain claims about how broadly it applies and how it should be weighed.

The secondary outcomes add context but do not establish a comprehensive safety profile. Several listed event counts are small, and the posted intervals do not exclude no difference. The absence of serious adverse events in the posted groups should be read as an observation from this trial, not as proof that serious harms cannot occur. The record does not report deaths, detailed adverse-event terms, or complete safety follow-up information.

In short, the registry results support a clear observed difference for the primary procedural endpoint in the trial groups. They do not settle questions about generalizability, clinical importance, unreported outcomes, rare harms, or effects in settings beyond the enrolled study population.

17. Why This Trial Matters Statistically

This trial illustrates why the definition of a clinical endpoint matters. “Anesthesia” is a broad concept, but the primary outcome is tied to a concrete action: completing a dental procedure without rescue injection. That makes the result easier to interpret operationally, while also narrowing what the result can answer. It does not directly describe pain intensity, duration, or every aspect of participant experience.

It also shows the value of presenting an absolute contrast alongside relative measures. The posted risk difference summarizes the change in the proportion with the defined event, while the risk ratio and odds ratio express the comparison on different scales. These measures can look quite different numerically, so readers should identify the scale and outcome before comparing estimates across studies or discussing their meaning.

The primary result and secondary outcomes also demonstrate the difference between a focused primary question and a collection of additional measures. The primary comparison is comparatively clear in the posted data, while several secondary event outcomes are based on small counts and have broad uncertainty. Without reported multiplicity procedures and analysis plans, the secondary findings should remain contextual rather than decisive.

Finally, the registry record makes visible the boundary between a result and a full statistical account. The outcome counts and comparison permit interpretation of the posted primary result, but the record does not report details such as the analysis population, missing-data handling, or the original sample-size rationale. A careful statistical reading recognizes both what the data show and which design and analysis questions remain unanswered.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record gives limited information about who was eligible beyond describing the study as involving adults. Detailed participant characteristics, eligibility criteria, and the number of participants screened or excluded are not reported in the registry record. This limits assessment of how closely the enrolled group represents a broader population of adults receiving dental procedures involving maxillary teeth.

The record does not describe the specific dental procedure in detail, the method used to determine whether anesthesia was sufficient, or how outcome assessment was standardized across centers. Although the study is identified as multicenter and triple-masked, the centers and the parties included in masking are not reported in the registry record. These omissions prevent a detailed assessment of implementation and potential variation in outcome measurement.

Analysis details are also limited. The registry record does not report the primary analysis population, a statistical analysis plan, covariate adjustment, missing-data handling, or multiplicity control. It does not report interim analyses or the original sample-size justification. These items should be treated as unknown, rather than inferred from the completed status or the posted outcome summaries.

The posted secondary results include sparse events, which limits precision for those comparisons. The registry record’s serious-event summary reports no affected participants, but the record does not supply detailed event terms or a complete description of safety follow-up. Deaths are not reported in the registry record. These limits mean the posted safety figures cannot resolve questions about rare harms or the full range of adverse experiences.

Finally, the primary endpoint is narrowly tied to procedure completion without rescue during the stated timeframe. It does not establish effects on outcomes that were not reported, and the registry record does not define a threshold for clinical importance. These are specific limits of the recorded evidence, not evidence that the unreported features had any particular value.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults — NCT01745380.
• Registry record last updated 2017-01-31; status last verified 2016-12.
• Results first posted 2017-01-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry record describes a completed phase 3, multicenter, randomized, triple-masked, parallel-groups trial of intranasal Kovacaine Mist versus placebo in adults undergoing a dental procedure involving maxillary teeth. The intervention is listed as tetracaine HCl 3% and oxymetazoline HCl 0.05%, with placebo as comparator.

The primary outcome counts participants who completed the study dental procedure without rescue injection at 15 minutes, with a +3 minute window. The posted counts are 88 of 100 for Kovacaine Mist and 14 of 50 for placebo. The unadjusted risk difference is 0.6, with an interval above zero, and p < 0.001.

Secondary outcomes include procedure completion by age group and heart-rate and blood-pressure measures. The posted serious adverse event figures are zero affected participants in both groups; deaths are not reported in the registry record. Important details about analysis populations, missing data, multiplicity, and the original sample-size justification are not reported in the registry record.